Fig. 3From: Development and validation of a new LC–MS/MS method for the determination of mefatinib in human plasma and its first application in pharmacokinetic studiesThe mean plasma concentration–time curves of NSCLC patients in different dose groups after single dosing of MET306. * The Mean ± SD plasma concentration–time profile of MET306 in human plasma following single oral administration of MET306 in different dose groups (A: 10 mg, B: 20 mg, C: 30 mg, D: 45 mg, E: 60 mg, F: 80 mg, G: 105 mg, H: 140 mg) to NSCLC patients (A: n = 1, B: n = 3, C: n = 3, D: n = 4, E: n = 4, F: n = 4, G: n = 5, H: n = 1)Back to article page